Jennifer Lauchle

发表

Isolation and analysis of candidate myeloid tumor suppressor genes from a commonly deleted segment of 7q22.

E. Green, M. L. Le Beau, K. Shannon, 2005, Genomics.

Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder.

M. L. Le Beau, K. Shannon, L. Parada, 2004, Blood.

Inherited predispositions and hyperactive Ras in myeloid leukemogenesis

M. Loh, K. Shannon, B. Braun, 2006, Pediatric blood & cancer.

Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice.

Jin Xu, S. Kogan, K. Shannon, 2013, The Journal of clinical investigation.

A MEK Inhibitor Abrogates Myeloproliferative Disease in Kras Mutant Mice

K. Shannon, W. Hong, B. Braun, 2011, Science Translational Medicine.

Response and Resistance to MEK Inhibition in Leukaemias Initiated by Hyperactive Ras

N. Jenkins, J. Sebolt-Leopold, K. Shannon, 2009, Nature.

Costello and cardio‐facio‐cutaneous syndromes: Moving toward clinical trials in RASopathies

S. Nadaf, F. McCormick, J. Sebolt-Leopold, 2011, American journal of medical genetics. Part C, Seminars in medical genetics.

A multicenter, single‐arm, open‐label, phase 2 study of apitolisib (GDC‐0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study)

Yulei N. Wang, J. Ware, J. Spoerke, 2016, Cancer.

Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors

M. Zauderer, R. Yeh, J. Ware, 2016, Clinical Cancer Research.

A Collaborative Model for Accelerating the Discovery and Translation of Cancer Therapies.

Benjamin S Braun, Ophélia Maertens, Mila E McCurrach, 2017, Cancer research.

Abstract B153: A phase I study evaluating the pharmacokinetics (PK) and pharmacodynamic (PD) activity of the dual PI3K/mTOR inhibitor GDC-0980 administered once weekly (QW).

G. Jayson, J. Ware, J. Soria, 2011 .

Clinical Translation: Targeting the Estrogen Receptor.

Ciara Metcalfe, Jennifer Lauchle, 2022, Advances in Experimental Medicine and Biology.

Targeting RAS Signaling Pathways in Juvenile Myelomonocytic Leukemia (JMML)

B. Braun, J. O. Lauchle, J. Lauchle, 2010 .

A first-in-human phase I study to evaluate GDC-0980, an oral PI3K/mTOR inhibitor, administered QD in patients with advanced solid tumors.

J. Ware, J. Bendell, H. Burris, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.